Octapharma
Octapharma AG, headquartered in Switzerland (CH), is a leading global player in the biopharmaceutical industry, specialising in the development and production of human proteins derived from human plasma and recombinant technologies. Founded in 1983, Octapharma has established a strong presence in Europe, North America, and Asia, with a commitment to innovation and quality. The company’s core product offerings include a range of immunoglobulins, coagulation factors, and albumin, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Octapharma is renowned for its dedication to patient safety and product efficacy, setting it apart in a competitive market. With a robust pipeline and a focus on research and development, Octapharma has achieved significant milestones, positioning itself as a trusted name in the biopharmaceutical sector, committed to improving patient outcomes worldwide.
DitchCarbon Score
How does Octapharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma's score of 67 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Octapharma's reported carbon emissions
In 2023, Octapharma reported total carbon emissions of approximately 177,000 kg CO2e, comprising 102,000 kg CO2e from Scope 1, 4,000 kg CO2e from Scope 2, and 71,000 kg CO2e from Scope 3 emissions. This marks a significant reduction of about 22% in overall emissions since 2019, when total emissions were approximately 228,000 kg CO2e in the UK. The company has set an ambitious target to achieve a 30% reduction in emissions by 2028. Globally, Octapharma's emissions for 2023 were reported at approximately 3,660 kg CO2e, with Scope 1 emissions at 1,530 kg CO2e, Scope 2 at 4,260 kg CO2e, and Scope 3 also at 1,530 kg CO2e. Looking ahead, Octapharma is committed to achieving Net Zero emissions by 2050, demonstrating its dedication to sustainability and climate responsibility. These initiatives align with industry standards and reflect a proactive approach to reducing carbon footprints across all scopes of emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 73,000 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 7,000 | 0,000 | 0,000 | 0,000 |
| Scope 3 | 156,000 | 0,000 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Octapharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
